The a2 Milk Company Limited logo

D&O Ongoing Disclosures – Multiple

Insider Disclosure16 March 2018ATMConsumer Staples

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and

Name of listed issuer:

The a2 Milk Company Limited

Date this disclosure made:

16/03/2018

Date of last disclosure:

29/08/2017

Director or senior manager giving disclosure

Full name(s):

Andrew CLARKE

Name of listed issuer:

The a2 Milk Company Limited (Company)

Name of related body corporate (if applicable):

Position held in listed issuer:Chief Scientific Officer

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products: Ordinary Shares

Nature of the affected relevant interest(s):

Legal and beneficial owner

For that relevant interest-


Number held in class before acquisition or disposal:500,000 Ordinary Shares (partly paid)

Number held in class after acquisition or disposal:500,000 Ordinary Shares (fully paid)

Current registered holder(s):

Andrew John Clarke & Susanna Katherine

Sinclair & Matthew Anderson Earles, as

trustees of The Clarke Sinclair Family Trust

Registered holder(s) once transfers are registered:

Andrew John Clarke & Susanna Katherine

Sinclair & Matthew Anderson Earles, as

trustees of The Clarke Sinclair Family Trust

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:

Class of underlying financial products:

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial

products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative(if any):

The price specified in the terms of the derivative (if any):

Any other details needed to understand how the amount of the consideration payable

under the derivative or the value of the derivative is affected by the value of the

underlying financial products:

For that derivative,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant

interest in the derivative:

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates: 1

Details of transactions requiring disclosure-

Date of transaction:

9/03/2018

Nature of transaction:

Payment up of 500,000 partly paid shares in

full

Name of any other party or parties to the transaction (if known):Unknown

The consideration, expressed in New Zealand dollars, paid or recieved for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a

cash value, describe the consideration:

$272,250 paid up on 500,000 partly paid

ordinary shares

Number of financial products to which the transaction related:

500,000 partly paid ordinary shares were

fully paid up

If the issuer has a financial products trading policy that prohibits directors or senior

managers from trading during any period without written clearance (a closed period)

include the following details—

Whether relevant interests were aquired or disposed of during a closed period:

No

Whether prior written clearance was provided to allow the aquisition or disposal to

proceed during the closed period:

N/A

Date of the prior written clearance (if any):

N/A

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

Nature of relevant interest:

For that relevant interest,-

Number held in class:

Current registered holder(s):

For a derivative relevant interest,-

Type of derivative:

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial

products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable

under the derivative or the value of the derivative is affected by the value of the

underlying financial products:

For that derivative relevant interest,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant

interest in the derivative:

Cerification

I certify that, to the best of my knowledge and belief, the information contained in this

disclosure is correct and that I am duly authorised to make this disclosure by all persons

for whom it is made.

Signature of director or officer:

Date of signature:16/03/2018

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:

Notes

Use this form to disclose all the aquisitions and disposals by a director or senior manager

of a listed issuer, or of a related body corporate, or in specified derivatives. The

disclosure must be made within—

(a) 20 working days after the first aquisition or disposal disclosed in this notice

if the aquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial

Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first aquisition or disposal

disclosed in this notice.

---

Appendix 3Y
Change of Director’s Interest Notice




+ See chapter 19 for defined terms.


01/01/2011 Appendix 3Y Page 1

(Rule 3.19A.2

Appendix 3Y


Change of Director’s Interest Notice


Information or documents not available now must be given to ASX as soon as available. Information and

documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11


Name of entity The a2 Milk Company Limited

ABN 97 769 415 292


We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for

the director for the purposes of section 205G of the Corporations Act.


Name of Director

Geoffrey Babidge

Date of last notice

1 March 2018


Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust


Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should

be disclosed in this part.


Direct or indirect interest

Indirect

Nature of indirect interest

(including registered holder)

Note: Provide details of the circumstances giving rise to the

relevant interest.

Geoffrey Babidge’s relevant interest is held on

trust by GCAA Investments Pty Ltd.

Date of change

9 March 2018

No. of securities held prior to change

2,000,000 partly paid ordinary shares.

500,000 fully paid ordinary shares.

Class

Fully paid ordinary shares and partly paid

ordinary shares.

Number acquired

2,000,000 fully paid ordinary shares.

Number disposed

2,000,000 partly paid ordinary shares (as a

result of the payment-up of those shares in

full).

Value/Consideration

Note: If consideration is non-cash, provide details and estimated

valuation

NZ$ 1,267,200 paid up on the partly paid

ordinary shares.

No. of securities held after change

2,500,000 fully paid ordinary shares.

Nature of change

Example: on-market trade, off-market trade, exercise of options, issue

of securities under dividend reinvestment plan, participation in buy-back

Full payment of 2,000,000 partly paid

ordinary shares.

Appendix 3Y
Change of Director’s Interest Notice




+ See chapter 19 for defined terms.


Appendix 3Y Page 2 01/01/2011

Part 2 – Change of director’s interests in contracts


Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should

be disclosed in this part.


Detail of contract

n/a

Nature of interest

n/a

Name of registered holder

(if issued securities)

n/a

Date of change

n/a

No. and class of securities to which

interest related prior to change

Note: Details are only required for a contract in

relation to which the interest has changed

n/a

Interest acquired

n/a

Interest disposed

n/a

Value/Consideration

Note: If consideration is non-cash, provide details

and an estimated valuation

n/a

Interest after change

n/a


Part 3 –

+

Closed period


Were the interests in the securities or contracts detailed

above traded during a

+

closed period where prior written

clearance was required?

No

If so, was prior written clearance provided to allow the trade

to proceed during this period?

n/a

If prior written clearance was provided, on what date was

this provided?

n/a

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.

  • NZX — NZX Limited: D&O Ongoing Disclosure – Jon Macdonald
    2017-12-21

    Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013 To NZX Limited; and Name of listed issuer: NZX Limited Date this disclosure made: 22-Dec-17 Date of last disclosure: 4-Sep-1…”

  • NZX — NZX Limited: D&O Ongoing Disclosures – Multiple
    2018-06-14

    Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013 To NZX Limited; and Name of listed issuer: NZX Limited Date this disclosure made: 15-Jun-18 Date of last disclosure: 3-May-1…”

  • OCA — Oceania Healthcare Limited: D&O Ongoing Disclosures – Multiple
    2018-01-25

    Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013 To NZX Limited; and ASX Name of listed issuer: Oceania Healthcare Limited Date this disclosure made: 26-Jan-18 Date of last di…”